Penumbra, Inc. PEN
320.43 USD -1.29 (-0.40%)
Nov 12, 2026, 10:10 AM EST
320.43 Day range 322.39
274.20 52-week range 362.41
- YTD
- +3.06%
- 1 year
- +14.32%
News
benzinga.com Penumbra Q3 EPS $1.07 Misses $1.25 Estimate, Sales $410.145M Beat $403.345M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.25 by 14.4 percent. This is a 10.31 percent increase over earnings of $0.97 per…
benzinga.com Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and…
benzinga.com Penumbra Presents Results From Subset Analysis Of STORM-PE Randomized Controlled Trial At Vascular InterVentional Advances Meeting Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recoveryALAMEDA,…
benzinga.com Incuvate Files Patent Infringement Lawsuit Against Penumbra Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California.The lawsuit, filed August 19,…- benzinga.com Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $0.88 per share which missed the analyst consensus estimate of $1.20 by 26.67 percent. This is a 23.48 percent decrease over earnings of $1.15 per…
benzinga.com Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will…- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $320 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and lowers the price target from $335 to $320.
- benzinga.com RBC Capital Reiterates Sector Perform on Penumbra, Maintains $374 Price Target RBC Capital analyst Shagun Singh reiterates Penumbra (NYSE:PEN) with a Sector Perform and maintains $374 price target.
- benzinga.com Penumbra's THUNDERBOLT Gets FDA Clearance To Treat Acute Ischemic Stroke Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted…
benzinga.com Citigroup Maintains Neutral on Penumbra, Lowers Price Target to $350 Citigroup analyst Joanne Wuensch maintains Penumbra (NYSE:PEN) with a Neutral and lowers the price target from $374 to $350.- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $335 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and lowers the price target from $345 to $335.
- benzinga.com Penumbra Q1 Adj. EPS $1.00 Misses $1.07 Estimate, Sales $374.758M Beat $371.104M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.00 per share which missed the analyst consensus estimate of $1.07 by 7.41 percent. This is a 0 percent increase over earnings of $1.00 per share…
benzinga.com 8 Stocks to Buy as Merger-Mania Takes Over Consolidation wave creates opportunities for patient investors. 8 sectors leading now are health, semiconductors, medical devices, and media.- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Raises Price Target to $360 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and raises the price target from $340 to $360.
benzinga.com Penumbra Q4 Earnings Assessment - benzinga.com Penumbra Q4 Adj. EPS $1.18 Beats $1.11 Estimate, Sales $385.385M Beat $366.795M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.11 by 6.12 percent. This is a 38.82 percent increase over earnings of $0.85 per…
benzinga.com Price Over Earnings Overview: Penumbra 
benzinga.com Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface FDA is reviewing AXIOS stent delivery issues after Boston Scientific reported injuries and deaths, urging facilities to stop use and remove affected devices.
benzinga.com RBC Capital Downgrades Penumbra to Sector Perform, Raises Price Target to $374 RBC Capital analyst Shagun Singh downgrades Penumbra (NYSE:PEN) from Outperform to Sector Perform and raises the price target from $355 to $374.- benzinga.com Canaccord Genuity Downgrades Penumbra to Hold, Raises Price Target to $374 Canaccord Genuity analyst Jason Mills downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $359 to $374.
- benzinga.com Jefferies Downgrades Penumbra to Hold, Raises Price Target to $374 Jefferies analyst Matthew Taylor downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $335 to $374.
- benzinga.com Citigroup Downgrades Penumbra to Neutral, Raises Price Target to $374 Citigroup analyst Joanne Wuensch downgrades Penumbra (NYSE:PEN) from Buy to Neutral and raises the price target from $350 to $374.
benzinga.com Honeywell To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Analyst Expectations For Penumbra's Future 
benzinga.com This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Baird Downgrades Penumbra to Neutral, Raises Price Target to $374 Baird analyst David Rescott downgrades Penumbra (NYSE:PEN) from Outperform to Neutral and raises the price target from $345 to $374.
- benzinga.com Truist Securities Downgrades Penumbra to Hold, Raises Price Target to $374 Truist Securities analyst Richard Newitter downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $370 to $374.
- benzinga.com Wells Fargo Downgrades Penumbra to Equal-Weight, Announces $374 Price Target Wells Fargo analyst Larry Biegelsen downgrades Penumbra (NYSE:PEN) from Overweight to Equal-Weight and announces $374 price target.
benzinga.com Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? U.S. stocks rallied near record territory on Thursday as blowout earnings from major Wall Street firms and renewed confidence in the AI trade lifted risk appetite.
benzinga.com Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday 
benzinga.com Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy Penumbra (PEN) climbs on strong Q4 results and acquisition agreement with Boston Scientific (BSX), deal valued at $14.5B.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expectations for Federal Reserve rate cuts later this year, as a weaker-than-expected start to the…- benzinga.com B of A Securities Maintains Buy on Penumbra, Raises Price Target to $370 B of A Securities analyst Travis Steed maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $320 to $370.
- benzinga.com Truist Securities Maintains Buy on Penumbra, Raises Price Target to $370 Truist Securities analyst Richard Newitter maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $312 to $370.
benzinga.com JP Morgan Upgrades Penumbra to Overweight, Raises Price Target to $370 JP Morgan analyst Robert Marcus upgrades Penumbra (NYSE:PEN) from Neutral to Overweight and raises the price target from $275 to $370.- benzinga.com Canaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $359 Canaccord Genuity analyst Jason Mills maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $355 to $359.
- benzinga.com Needham Maintains Buy on Penumbra, Raises Price Target to $388 Needham analyst Mike Matson maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $326 to $388.
benzinga.com Citigroup Upgrades Penumbra to Buy, Raises Price Target to $350 Citigroup analyst Joanne Wuensch upgrades Penumbra (NYSE:PEN) from Neutral to Buy and raises the price target from $285 to $350.- benzinga.com Here's How Much $1000 Invested In Penumbra 10 Years Ago Would Be Worth Today
- benzinga.com Here's How Much You Would Have Made Owning Penumbra Stock In The Last 10 Years
- benzinga.com Here's How Much $1000 Invested In Penumbra 10 Years Ago Would Be Worth Today
- benzinga.com Looking Into Penumbra Inc's Recent Short Interest
benzinga.com Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.- benzinga.com Canaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $355 Canaccord Genuity analyst Jason Mills maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $350 to $355.
benzinga.com Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday 
benzinga.com Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be…- benzinga.com A Look Into Penumbra Inc's Price Over Earnings
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Penumbra Presents STORM-PE Results At VIVA 2025; Trial Data Shows CAVT Plus Anticoagulation Improves Functional Outcomes Than Anticoagulation Alone In PE Patients The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden…